Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-09-10
2011-12-06
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S037000, C514S039000, C514S041000, C514S043000, C536S013200, C536S013600, C536S013700, C536S022100
Reexamination Certificate
active
08071535
ABSTRACT:
Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates.
REFERENCES:
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4749800 (1988-06-01), Jobe et al.
patent: 6525182 (2003-02-01), Goodman et al.
patent: WO 2005/025513 (2005-03-01), None
International Search Report and Written Opinion dated Jul. 20, 2005 for PCT/US04/29880, filed Sep. 10, 2004, (8 pages).
Baba, M. et al., “HIV-1-Specific Reverse Transcriptase Inhibitors,” Chapter 11 in Anti-Aids Drug Development: Challenges, Strategies and Prospects, P. Mohan and M. Baba (Editors), Harwood Academic Publishers GmbH, Switzerland, 1995, pp. 239-267.
Baker, T.J. et al., “Synthesis and Anti-HIV activity of Guanidinoglycosides,” J. Org. Chem., 65: 9054-9058 (2000).
Check, E., “HIV Drug Resistance Triggers Strategic Switch,” Nature 424: 361 (Jul. 24, 2003).
De Clercq, Erik, “From Anti-HIV Agents to Anti-AIDS Chemotherapy: A Critiical Appraisal,” Chapter 1 in Anti-AIDS Drug Development: Challenges, Strategies and Prospects, P. Mohan and M. Baba (Editors), Harwood Academic Publishers GmbH, Switzerland, 1995, pp. 1-37.
Frankel, A.D. and J.A.T. Young, “HIV-1: Fifteen Proteins and an RNA,” Annu. Rev. Biochem. 67: 1-25 (1998).
Greenwald, R.B. et al., “Drug Delivery Systems employing 1,4- or 1,6-Eliminations: Poly(ethylene glycol) Prodrugs of Amino-containing Compounds,” J. Med. Chem. 42: 3657-3667 (1999).
Jeong, L.S. et al., “Nucelosides and Derivative,” Chapter 2 in Anti-AIDS Drug Development: Challenges, Strategies and Prospects, P. Mohan and M. Baba (Editors), Harwood Academic Publishers GmbH, Switzerland, 1995, pp. 39-63.
Kirk, S.R. et al., “Neomycin-Acridine Conjugate: A Potent Inhibitor of Rev-RRE Binding,” J. Am. Chem. Soc. 122: 980-981 (2000).
Luedtke, N.W. and Y . Tor, “A Novel Solid-Phase Assembly for Identifying Potent and Selective RNA Ligands,” Angew. Chem. Int. Ed. 39(10): 1788-1790 (2000).
Luedtke, N.W. et al., “Guanidinoglycosides: A Novel Family of RNA Ligands,” J. Am. Chem. Soc. 122: 12035-12036 (2000).
Pollard, V.M. and M.H. Pollard, “The HIV-1 Rev Protein” Annu. Rev. Microbiol. 52: 491-532 (1998).
Joint United Nations Programme on HIV/AIDS (UNAIDS),Report on the Global HIV/AIDS Epidemic 2002, Switzerland, UNAIDS/02.26E, ISBN 92-1973-185-4 , 229 pages (Jul. 2002).
Wakselman, M., “1,4- and 1,6-eliminations from hydroxyl and and amino-substituted benzyl systems: chemical and biochemical applications,” Nouveau Journal De Chimie, 7(7): 439-447 (Jul. 1983).
Wang, H. and Y. Tor, “Dimeric Aminoglycosides: Design, Synthesis and RNA Binding,” Bioorganic & Medicinal Chemistry Letters, 7(14): 1951-1956 (1997).
Wang, H. and Y. Tor, “Tobramycin-EDTA Conjugate: A Noninnocent Affinity-Cleaving Reagent,”, Bioorg. Med. Chem. Lett. (1998) 8: 3665-3670 (1998).
Wang, H. and Y. Tor, “Electrostatic Interactions in RNA Aminoglycosides Binding,” J. Am. Chem Soc. 119:8734-8735 (1997).
Luedtke Nathan
Tor Yitzhak
Fish & Richardson P.C.
Peselev Elli
The Regents of the University of California
LandOfFree
Guanidinium derivatives for improved cellular transport does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidinium derivatives for improved cellular transport, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidinium derivatives for improved cellular transport will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262718